Urinary incontinence is the involuntary discharge of urine. Pets can be incontinent for many different reasons. Those reasons can involve the bladder, the urethra -which is the tube from the bladder to the outside-, or incontinence can be caused by abnormalities in the parts of the brain and spinal cord that control bladder function. Since the role of pets in families has evolved and is now considered an important member. Their health and welfare is gaining relevance day-to-day, and the number of pet is growing annually (78 million dogs in the United States and 81 million dogs in Europe). As such, the market to solve pet's health problems is also growing rapidly. In fact, there is already a pharmaceutical product in the market: Phenylpropanolamine Hydrochloride (PPA), indicated to solve Stress Urinary Incontinence (PMSI) in dogs. However, it suffers significant limitations such as inconveniences, safety and efficacy issues as well as price ($15-25/month). Problematic side effects including death (banned for humans) and many dogs eventually become non-responsive (about 20%).
We have created a new material: CellFoam™ is a novel biomaterial offering a true revolution in the field of tissue engineering due to its capacity as a scaffold and tissue adhesive.
CellFoam™ can solve in one short endoscopic procedure the unmet needs of urinary incontinence. It will provide long-term efficacy, quality of life reassurance for dogs and also for their owners.
Our objective is to accelerate the market adoption and international penetration of CellFoam™, focusing ourselves on reducing the risks (commercial, technical and financial) and preparing for the commercialization at the international level (including route-to-market, marketing strategy, growth strategy, etc.). Thus, we pursue to minimize the risks and maximize the chances of success while creating a business that is financially sustainable and can have positive cash flow in the long run.
